Structured evidence table for Ergothioneine Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Ergothioneine Cognition Randomized Trial | Cognitive frailty not only affects the quality of life of older adults but also significantly increases the risk of severe adverse outcomes such as dementia and disability []. | 3 | Gede Arjun M. M. I. (2025) | Advances and prospects of ergothioneine in the treatment of cognitive frailty |
| Ergothioneine Cognition Randomized Trial | Research has demonstrated that ERGO exhibits significant protective effects against 7-ketocholesterol (7KC)-induced mitochondrial damage in human brain endothelial cells, as evidenced by improved cell viability, reduced intracellular calcium levels, decreased reactive oxygen species, and modulated expression of inflammatory markers []. | 3 | Gede Arjun M. M. I. (2025) | Advances and prospects of ergothioneine in the treatment of cognitive frailty |
| Ergothioneine Cognition Randomized Trial | In numerous studies on the severity of coronavirus infection, hypoxia-induced respiratory distress, cytokine storm-induced central nervous system (CNS) inflammatory damage, and hypercoagulability leading to cerebral venous thrombosis or stroke have all been identified as major risk factors for mortality or severe symptoms []. | 3 | Gede Arjun M. M. I. (2025) | Advances and prospects of ergothioneine in the treatment of cognitive frailty |
| Ergothioneine Cognition Randomized Trial | 1 2 3 4 Cognitive frailty, first formally proposed by the International Society of Nutrition and Aging and the International Geriatrics and Gerontology Association in 2013, is a clinical state where physical frailty and cognitive impairment coexist. | 3 | Gede Arjun M. M. I. (2025) | Advances and prospects of ergothioneine in the treatment of cognitive frailty |
| Ergothioneine Cognition Randomized Trial | Emerging evidence in the role of mushroom in promoting cognition has been produced from limited observational studies but there is a lack of definitive evidence on both longitudinal relationships from prospective cohort studies and clinical efficacy from clinical trials. | 4 | Shan J (2025) | Study protocol: The efficacy of mushroom to prevent cognitive decline in at-risk middle-aged adults and young-olds living in the community. |
| Ergothioneine Cognition Randomized Trial | Objectives To explore the definitive evidence of mushroom on cognitive functions among at-risk middle-aged and young-olds. | 4 | Shan J (2025) | Study protocol: The efficacy of mushroom to prevent cognitive decline in at-risk middle-aged adults and young-olds living in the community. |
| Ergothioneine Cognition Randomized Trial | Background Cognitive function declines with increasing age and maintaining high cognitive functioning especially at late life remains a challenging question to be addressed. | 4 | Shan J (2025) | Study protocol: The efficacy of mushroom to prevent cognitive decline in at-risk middle-aged adults and young-olds living in the community. |
Source documents